Drug interactions between Norvir and pravastatin
| Results for the following 2 drugs: |
|---|
| Norvir (ritonavir) |
| pravastatin |
Interactions between your selected drugs
pravastatin ↔ ritonavir
Applies to:pravastatin and Norvir (ritonavir)
MONITOR: Coadministration with ritonavir may decrease the plasma concentrations of pravastatin. The proposed mechanism is ritonavir induction of pravastatin metabolism via glucuronosyl transferase. In 13 healthy volunteers, the combination of ritonavir (300 mg twice a day for 3 days, then 400 mg twice a day) and saquinavir (soft gelatin capsule 400 mg twice a day) given for 14 days decreased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of pravastatin (40 mg once a day for 4 days) by 42% and 50%, respectively. The clinical relevance of these changes is unknown. Pravastatin appeared to have no significant effect on the plasma levels of ritonavir and saquinavir based on comparison with historical controls. It is not known to what extent, if any, the interaction may occur when ritonavir is used in lower dosages as a pharmacokinetic booster. No interaction was observed when pravastatin was given with lopinavir-ritonavir in drug interaction studies.
MANAGEMENT: Pravastatin appears to be safe when coadministered with ritonavir, although the potential for diminished hypolipidemic efficacy should be considered when antiretroviral dosages of ritonavir is prescribed. Pharmacologic response to pravastatin should be monitored more closely whenever ritonavir is added to or withdrawn from therapy, and the pravastatin dosage adjusted as necessary.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
